All News

Patients with relapsed/refractory myeloma continued to experience durable and efficacious responses after treatment with ciltacabtagene autoleucel.

Patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma experienced efficacious survival benefits from treatment with primary radiotherapy.

Although there was no resulting benefit to overall survival with the addition of short-term androgen deprivation to dose-escalated radiotherapy, patients with intermediate-risk prostate cancer experienced other disease benefits with this treatment approach.

Patients receiving trastuzumab for HER2-positive breast cancer on the phase 3 HERA trial did not have an increased risk of cardiotoxicity from radiation therapy.

Patients who were treated with extreme hypofractionation after breast conserving surgery saw no increase in ill-treatment effects compared with those receiving moderate hypofractionation.

Patients with advanced biliary tract cancer received a clinically meaningful and statistically significant overall survival benefit after being treated with durvalumab and chemotherapy.

A retrospective review found that external-beam radiation therapy has been underutilized as a bridging therapy in patients with hepatocellular carcinoma seeking transplant, although its prevalence has increased over the past decade.

Investigators believe that a systems-based intervention could reduce or even eliminate racial gaps in cancer treatment completion and improve outcomes.

CancerNetwork® spoke with Debra Patt, MD, PhD, MBA, about the role of telehealth in caring for patients with cancer during the COVID-19 pandemic and beyond.

Patients with platinum-resistant ovarian cancer appear to benefit from treatment with nemvaleukin alfa and pembrolizumab, a combination which was granted a fast track designation for this indication by the FDA.

Stereotactic body radiotherapy added to standard of care treatment resulted in better progression-free survival for those with oligoprogressive non–small cell lung cancer.

Following discussion with the FDA, INN melphalan flufenamide has been withdrawn from market in the United States based on data from the phase 3 OCEAN study.

Despite not meeting its primary end point of superior progression-free survival, the phase 3 SOLSTICE trial’s secondary end point analysis will continue in patients with unresectable metastatic colorectal cancer being treated with trifluridine/tipiracil and bevacizumab.

The VENTANA PD-L1 Assay, a companion diagnostic for atezolizumab in select patients with non–small cell lung cancer, was approved by the FDA based on the phase 3 Impower010 trial.

CancerNetwork® sat down with Lyudmilia Bazhenova, MD, at the 2021 World Conference on Lung Cancer to discuss differences in outcomes with immunotherapy agents in patients with wild-type and EGFR exon 20 insertion–positive non–small cell lung cancer.

In patients with bacillus Calmette-Guérun–unresponsive non-muscle invasive bladder cancer who are being treated with nadofaragene firadenovec, elevated levels of antibody titers may be able to predict efficacy.

In a debate, experts discuss the importance of IGHV and TP53 mutational status in predicting response to novel therapies in chronic lymphocytic leukemia.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to highlight key lessons that COVID-19 pandemic taught him.

CancerNetwork® sat down with Lyudmilia Bazhenova, MD, at the 2021 World Conference on Lung Cancer to talk about the feasibility of immunotherapy trials in wild-type and EGFR exon 20 insertion non–small cell lung cancer.

The interim results of a phase 1b/2 trial showed that patients with soft tissue sarcoma and lung metastases who were treated with annamycin experienced positive clinical activity.

BXCL701 and pembrolizumab may resolve the need for FDA-approved therapies for patients with small cell neuroendocrine prostate cancer, according to investigators.

Brian I. Rini, MD, detailed the focus, goals, and key end points of a 3-arm, phase 3 trial comparing MK-1308A or belzutifan plus lenvatinib and pembrolizumab to the control of lenvatinib and pembrolizumab alone to treat patients with advanced clear cell renal cell carcinoma.

A phase 2 trial examining the use of small molecule immunomodulator EC-18 in patients with head and neck cancer experiencing chemoradiation-induced oral mucositis met its primary and secondary end points.

Patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer experienced a progression-free survival benefit after being treated with elacestrant.

Investigators compared tradeoffs in breast cancer screening strategies in Black patients vs White patients.

Patients with Bacillus Calmette-Guerin–unresponsive non-muscle invasive bladder cancer experienced a disease-free survival benefit when treated with intravesical Bacillus Calmette-Guerin and a novel IL-15 superagonist complex .

The FDA issued a complete response letter to the company responsible for developing narsoplimab because of the inability to estimate treatment effects on patients receiving hematopoietic stem cell transplant–associated thrombotic microangiopathy.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about how the COVID-19 pandemic affected his work and how they adapted.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to discuss the benefit of treatment with daratumumab, carfilzomib, lenalidomide, and dexamethasone and the population of patients with newly diagnosed myeloma who will best benefit from treatment.

A retrospective review identified that clinical practice patterns have changed from 2002 to 2020, with the use of immunotherapy increasing as chemotherapy and radiation therapy use has decreased for patients with Merkel cell carcinoma.